Literature DB >> 14503435

Methods for a multisite randomized trial to investigate the effect of constraint-induced movement therapy in improving upper extremity function among adults recovering from a cerebrovascular stroke.

Carolee J Winstein1, J Philip Miller, Sarah Blanton, Edward Taub, Gitendra Uswatte, David Morris, Deborah Nichols, Steven Wolf.   

Abstract

This article describes the study design, methodological considerations, and demographic characteristics of a phase III RCT to determine if 1) constraint-induced therapy (CI therapy) can be applied with therapeutic success 3 to 9 months after stroke across different sites, 2) gains that might occur persist over 2 years, 3) initial level of motor ability determines responsiveness to CI therapy, and 4) the treatment effect differs between those treated before 9 months and after 1 year. Six sites will screen and recruit poststroke survivors stratified on initial level of motor ability and after randomization allocate participants to immediate or delayed intervention. Primary outcomes include a laboratory-based measure of function (Wolf Motor Function Test [WMFT]) and a real-world participant-centered functional use measure (Motor Activity Log [MAI]). Secondary outcomes concern function, behavior, and compliance. This is the first multisite, single-blind RCT of a formal training intervention for upper extremity rehabilitation in subacute stroke in the United States.

Entities:  

Mesh:

Year:  2003        PMID: 14503435     DOI: 10.1177/0888439003255511

Source DB:  PubMed          Journal:  Neurorehabil Neural Repair        ISSN: 1545-9683            Impact factor:   3.919


  61 in total

1.  The EXCITE Trial: analysis of "noncompleted" Wolf Motor Function Test items.

Authors:  Steven L Wolf; Paul A Thompson; Emily Estes; Timothy Lonergan; Rozina Merchant; Natasha Richardson
Journal:  Neurorehabil Neural Repair       Date:  2011-11-09       Impact factor: 3.919

Review 2.  Strategies for stroke rehabilitation.

Authors:  Bruce H Dobkin
Journal:  Lancet Neurol       Date:  2004-09       Impact factor: 44.182

3.  Minimal detectable change of the actual amount of use test and the motor activity log: the EXCITE Trial.

Authors:  Shuya Chen; Steven L Wolf; Qin Zhang; Paul A Thompson; Carolee J Winstein
Journal:  Neurorehabil Neural Repair       Date:  2012-01-24       Impact factor: 3.919

4.  The effects of constraint-induced therapy on precision grip: a preliminary study.

Authors:  Jay L Alberts; Andrew J Butler; Steven L Wolf
Journal:  Neurorehabil Neural Repair       Date:  2004-12       Impact factor: 3.919

Review 5.  Contemporary linkages between EMG, kinetics and stroke rehabilitation.

Authors:  Steven L Wolf; Andrew J Butler; Jay L Alberts; Min Wook Kim
Journal:  J Electromyogr Kinesiol       Date:  2005-06       Impact factor: 2.368

6.  Rehabilitation and functional neuroimaging dose-response trajectories for clinical trials.

Authors:  Bruce H Dobkin
Journal:  Neurorehabil Neural Repair       Date:  2005-12       Impact factor: 3.919

Review 7.  Confounders in rehabilitation trials of task-oriented training: lessons from the designs of the EXCITE and SCILT multicenter trials.

Authors:  Bruce H Dobkin
Journal:  Neurorehabil Neural Repair       Date:  2007 Jan-Feb       Impact factor: 3.919

Review 8.  Brain-computer interface technology as a tool to augment plasticity and outcomes for neurological rehabilitation.

Authors:  Bruce H Dobkin
Journal:  J Physiol       Date:  2006-11-09       Impact factor: 5.182

9.  Evolution of FMRI activation in the perilesional primary motor cortex and cerebellum with rehabilitation training-related motor gains after stroke: a pilot study.

Authors:  Yun Dong; Carolee J Winstein; Richard Albistegui-DuBois; Bruce H Dobkin
Journal:  Neurorehabil Neural Repair       Date:  2007-03-16       Impact factor: 3.919

Review 10.  Fatigue versus activity-dependent fatigability in patients with central or peripheral motor impairments.

Authors:  Bruce H Dobkin
Journal:  Neurorehabil Neural Repair       Date:  2008 Mar-Apr       Impact factor: 3.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.